Ranibizumab for myopic choroidal neovascularization
Review of books or of software

香港中文大學研究人員
替代計量分析
.

其它資訊
摘要Introduction: Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic CNV. Areas covered: Review of preclinical studies and clinical trials data supporting the use of ranibizumab for myopic CNV. Discussion on the mechanisms, efficacy, safety, regulatory affairs, and future directions of ranibizumab for myopic CNV are highlighted. Expert opinion: Ranibizumab has demonstrated good efficacy and safety profile in multiple clinical trials and long-term studies for treating myopic CNV. Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently available anti-VEGF agents, ranibizumab is the only drug that is approved for the treatment of myopic CNV by the US Food and Drug Administration. In the coming few years, biosimilars of ranibizumab may become available and will have the potential to lower the cost of ranibizumab. Long-term visual gain after ranibizumab treatment for myopic CNV is limited by chorioretinal atrophy associated with pathologic myopia and further research is required to tackle the development of chorioretinal atrophy.
著者Ng DSC, Fung NSK, Yip FLT, Lai TYY
期刊名稱Expert opinion on biological therapy
出版作品名稱Expert Opinion on Biological Therapy
出版年份2020
卷號20
期次12
出版社Taylor and Francis Ltd.
頁次1385 - 1393
國際標準期刊號1471-2598
語言英式英語

上次更新時間 2021-28-11 於 00:14